Trinity Biotech Gross Profit vs. Revenue

TRIB Stock  USD 1.22  0.08  6.15%   
Considering the key profitability indicators obtained from Trinity Biotech's historical financial statements, Trinity Biotech plc may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Trinity Biotech's ability to earn profits and add value for shareholders.
 
Gross Profit  
First Reported
1993-03-31
Previous Quarter
5.7 M
Current Value
5.3 M
Quarterly Volatility
5.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Trinity Biotech's Days Sales Outstanding is projected to slightly grow based on the last few years of reporting. The current year's Days Of Sales Outstanding is expected to grow to 88.98, whereas Price To Sales Ratio is forecasted to decline to 0.28. At present, Trinity Biotech's Accumulated Other Comprehensive Income is projected to decrease significantly based on the last few years of reporting. The current year's Net Income Applicable To Common Shares is expected to grow to about 826.9 K, whereas Operating Income is projected to grow to (25.7 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.330.3422
Sufficiently Down
Pretty Stable
For Trinity Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Trinity Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Trinity Biotech plc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Trinity Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Trinity Biotech plc over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(2.25)
Revenue Per Share
6.968
Quarterly Revenue Growth
0.14
Return On Assets
(0.1)
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trinity Biotech plc Revenue vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Trinity Biotech's current stock value. Our valuation model uses many indicators to compare Trinity Biotech value to that of its competitors to determine the firm's financial worth.
Trinity Biotech plc is rated below average in gross profit category among its peers. It is rated below average in revenue category among its peers totaling about  1.49  of Revenue per Gross Profit. At present, Trinity Biotech's Gross Profit is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Trinity Biotech's earnings, one of the primary drivers of an investment's value.

Trinity Revenue vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Trinity Biotech

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
38.08 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Trinity Biotech

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
56.83 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Trinity Revenue vs Competition

Trinity Biotech plc is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 3.33 Billion. Trinity Biotech claims roughly 56.83 Million in revenue contributing just under 2% to equities under Health Care industry.

Trinity Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Trinity Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Trinity Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Trinity Biotech's change in net profit over the period of time. It can combine multiple indicators of Trinity Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeM1.1 M
Operating Income-27 M-25.7 M
Income Before Tax-36.9 M-35.1 M
Total Other Income Expense Net-9.9 M-9.4 M
Net Loss-24 M-22.8 M
Income Tax Expense-59 K-56 K
Net Income Applicable To Common Shares787.5 K826.9 K
Net Loss-36.9 M-35 M
Net Interest Income-9.9 M-10.4 M
Change To Netincome14.7 M14 M
Net Loss(3.14)(2.98)
Income Quality 0.48  0.82 
Net Income Per E B T 0.65  0.68 

Trinity Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Trinity Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Trinity Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Trinity Biotech's important profitability drivers and their relationship over time.

Use Trinity Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Trinity Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Trinity Biotech will appreciate offsetting losses from the drop in the long position's value.

Trinity Biotech Pair Trading

Trinity Biotech plc Pair Trading Analysis

The ability to find closely correlated positions to Trinity Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Trinity Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Trinity Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Trinity Biotech plc to buy it.
The correlation of Trinity Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Trinity Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Trinity Biotech plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Trinity Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Trinity Biotech position

In addition to having Trinity Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Giant Impact Thematic Idea Now

Giant Impact
Giant Impact Theme
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:
Check out World Market Map.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Trinity Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Trinity Biotech plc at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Trinity Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential Trinity Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Trinity Biotech investors may work on each financial statement separately, they are all related. The changes in Trinity Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Trinity Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.